Bioabsorbable polymeric drug-eluting endovascular stents: A clinical review

Minerva Biotecnologica

Volumn 21, Issue 4, 2009, Pages 217-230

  Soares, J S ^a,b  

^a POLITECNICO DI MILANO   (Italy)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

Absorption; Atherosclerosis; Balloon angioplasty; Degradation; Erosion; Scission

Indexed keywords

COLLAGEN TYPE 1; DEXAMETHASONE; EVEROLIMUS; HEPARIN; HYDROXYBUTYRIC ACID; IODINE; MAGNESIUM; NYLON; PACLITAXEL; POLY (4 HYDROXYBUTYRATE); POLYCAPROLACTONE; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYURETHAN; RAPAMYCIN; SILICONE; TYROSINE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BIODEGRADABILITY; BIODEGRADABLE POLYMERIC DRUG ELUTING STENT; CORONARY STENT; DRUG ELUTING STENT; DRUG MECHANISM; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; STENT THROMBOSIS; URETER STENT;

EID: 77951807093     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Dotter CT. Transluminal angioplasty: a long view. Radiology 1980;135:561-564
2. Lipinski MJ, Fearon WF, Froelicher VF, Vetrovec GW. The current and future role of percutaneous coronary intervention in patients with coronary artery disease. J Interv Cardiol 2004;17:283-294
3. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994;89:2888-2891
4. Muller DW, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992;19:418-432
5. Douglas JS Jr, King SB 3rd, Roubin GS. Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis. Am J Cardiol 1987;60:29B-33B.
6. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-706
7. Palmaz JC. Balloon-expandable intravascular stent. AJR Am J Roentgenol 1988;150:1263-1269
8. Schatz RA. Introduction to intravascular stents. Cardiol Clin 1988;6:357-372
9. Serruys PW, Dejaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary-artery disease. N Engl J Med 1994;331:489-495
10. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary-artery disease. N Engl J Med 1994;331:496-501.
11. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-566
12. Kastrati A, Hall D, Schomig A. Long-term outcome after coronary stenting. Curr Contr Trials C 2000;1:48-54.
13. Schillinger M, Minar E. Past, present and future of femoropopliteal stenting. J Endovasc Ther 2009;16(Suppl 1):1147-1152
14. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998;81:4E-6E.
15. Robaina S, Jayachandran B, He Y, Frank A, Moreno MR, Schoephoerster RT et al. Platelet adhesion to simulated stented surfaces. J Endovasc Ther 2003;10:978-986
16. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995,91:2995-3001.
17. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002;105:2974-2980 (Pubitemid 34693829)
18. Bedoya J, Meyer CA, Timmins LH, Moreno MR, Moore JE. Effects of stent design parameters on normal artery wall mechanics. J Biomech Eng 2006;128:757-765 (Pubitemid 44622805)
19. Glagov S, Zarins CK, Masawa N, Xu CP, Bassiouny H, Giddens DP. Mechanical functional role of non-atherosclerotic intimai thickening. Front Med Biol Eng 1993;5:37-43.
20. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994;90:2070-2084
21. Lambert TL, Dev V, Rechavia E, Forrester JS, Litvack F, Eigler NL. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin. Circulation 1994;90:1003-1011
22. Ahn YK, Jeong MH, Kim JW, Kim SH, Cho JH, Cho JG et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999;48:324-330
23. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997;29:808-816
24. Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32: 780-786 (Pubitemid 28435269)
25. Ye YW, Landau C, Willard JE, Rajasubramanian G, Moskowitz A, Aziz S et al. Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 1998;26:398-408. (Pubitemid 128609281)
26. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645 (Pubitemid 27329445)
27. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-Fkbp inhibits cell-cycle regulators of proliferation in vascular smooth-muscle cells. Circ Res 1995;76:412-417
28. Grube E, Gerckens U, Muller R, Bullesfeld L. Drug eluting stents: initial experiences. Z Kardiol 2002;91:44-48 (Pubitemid 34809724)
29. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780 (Pubitemid 34586912)
30. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A et al. Sirolimus-eluting vs. uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-2734 (Pubitemid 39628251)
31. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42. (Pubitemid 36070930)
32. Stone GW, Ellis SG, Cox DA, HermillerJ, O'Shaughnessy C, Mann JT et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947
33. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819-825 (Pubitemid 41175725)
34. Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 2004;5(Suppl 2):S3-8.
35. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006;98:464-9.
36. Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J 2009;158:520-526 e2.
37. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006;19:405-413
38. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
39. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW et al. Comparison of zotarolimus-eluting and sirolimuseluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-2447
40. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009;2:977-985
41. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
42. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
43. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521 (Pubitemid 39410418)
44. Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007;116:910-916
45. Klomp M, Beijk MA, de Winter RJ. Genous endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Rev Med Devices 2009;6:365-375
46. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985;5:293-302.
47. Cheng CP, Wilson NM, Hallett RL, Herfkens RJ, Taylor CA. In vivo MR angiographic quantification of axial and twisting deformations of the superficial femoral artery resulting from maximum hip and knee flexion. J Vasc Interv Radiol 2006:17:979-987
48. Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A et al Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-1509
49. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-338
50. Colombo A, Karvouni E. Biodegradable Stents : "Fulfilling the Mission and Stepping Away". Circulation 2000;102:371-373
51. Laufman H, Rubel T. Synthetic absorable sutures. Surg Gynecol Obstet 1977;145:597-608.
52. Pietrzak WS, Verstynen ML, Sarver DR. Bioabsorbable fixation devices: status for the craniomaxillofacial surgeon. J Craniofac Surg 1997;8:92-96
53. Langer R. Drug delivery and targeting. Nature 1998;392:5-10.
54. Agrawal CM, Ray RB. Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. J Biomed Mater Res 2001;55:141-50.
55. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP et al Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 1988;62:3F-24F.
56. Agrawal CM, Clark HG. Deformation characteristics of a bioabsorbable intravascular stent. Invest Radiol 1992;27:1020-1024
57. Agrawal CM, Haas KF, Leopold DA, Clark HG. Evaluation of poly(L-lactic acid) as a material for intravascular polymeric stents. Biomaterials 1992;13:176-182
58. Tanguay JF, Zidar JP, Phillips HR 3rd, Stack RS. Current status of biodegradable stents. Cardiol Clin 1994;12:699-713.
59. Labinaz M, Zidar JP, Stack RS, Phillips HR. Biodegradable stents: the future of interventional cardiology? J Interv Cardiol 1995;8:395-405.
60. Bier JD, Zalesky P, Li ST, Sasken H, Williams DO. A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics. J Interv Cardiol 1992;5:187-94.
61. Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24:525-531
62. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002;106:2859-2866
63. Peng T, Gibula P, Yao K-d, Goosen MFA. Role of polymers in improving the results of stenting in coronary arteries. Biomaterials 1996;17:685-694
64. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR, Jr. Percutaneous polymeric stents in porcine coronary arteries. Initial experience with polyethylene terephthalate stents. Circulation 1992;86:1596-1604
65. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-1697
66. De Scheerder IK, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E et al. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995;114:105-114
67. De Scheerder IK, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E et al. Biocompatibility of biodegradable and non-biodegradable polymer-coated stents implanted in porcine periph-eral arteries. Cardiovasc Intervent Radiol 1995;18:227-232
68. Zidar J, Lincoff A, Stack R. Biodegradable stents. In: Topol EJ, editor. Textbook of interventional cardiolology. 2nd ed. Philadelphia, PA: WB Saunders; 1994. p. 787-802.
69. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S et al. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
70. Tamai H, Igaki K, Tsuji T, Kyo E, Kosuga K, Kawashima A et al. A biodegradable poly-L-lactic acid coronary stent in the porcine coronary artery. J Interv Cardiol 1999;12:443-449
71. Tsuji T, Tamai H, Igaki K, Kyo E, Kosuga K, Hata T et al. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 2003;5:13-16
72. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv 2007;69:128-131
73. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
74. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM et al. A bioabsorbable everolimus-eluting coronary stent System (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
75. Ramcharitar S, Serruys PW. Fully biodegradable coronary stents : progress to date. Am J Cardiovasc Drugs 2008;8:305-314
76. Peuster M, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart 2001;86:563-569 (Pubitemid 32999872)
77. Peuster M, Hesse C, Schloo T, Fink C, Beerbaum P, von Schnakenburg C. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 2006;27:4955-4962 (Pubitemid 43866928)
78. Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003;89:651-656
79. Di Mario C, Griffiths H, Goktekin O, Peeters N, Verbist J, Bosiers M et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 2004;17:391-395
80. Drynda A, Deinet N, Braun N, Peuster M. Rare earth metals used in biodegradable magnesium-based stents do not interfere with proliferation of smooth muscle cells but do induce the upregulation of inflammatory genes. J Biomed Mater Res A 2009;91:360-369
81. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-1875
82. Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv 2009;2:312-320
83. Maeng M, Jensen LO, Falk E, Andersen HR, Thuesen L. Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. Heart 2009;95:241-246
84. Bosiers M, Peeters P, D'Archambeau O, Hendriks J, Pilger E, Duber C et al. AMS INSIGHT - absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol 2009;32:424-435
85. Rajasubramanian G, Meidell RS, Landau C, Dollar ML, Holt DB, Willard JE et al. Fabrication of resorbable microporous intravascular stents for gene therapy applications. ASAIO J 1994;40:M584-9. (Pubitemid 24364270)
86. Su SH, Chao RY, Landau CL, Nelson KD, Timmons RB, Meidell RS et al. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann Biomed Eng 2003;31:667-677
87. Zilberman M, Schwade ND, Eberhart RC. Protein-loaded bioresorbable fibers and expandable stents: Mechanical properties and protein release. J Biomed Mater Res B 2004;69:1-10. (Pubitemid 38391992)
88. Zilberman M, Nelson KD, Eberhart RC. Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiber-based stents. J Biomed Mater Res B 2005;74:792-799 (Pubitemid 41076951)
89. Welch T, Eberhart RC, Chuong CJ. Characterizing the expansive deformation of a bioresorbable polymer fiber stent. Ann Biomed Eng 2008;36:742-751
90. Grabow N, Schlun M, Sternberg K, Hakansson N, Kramer S, Schmitz KP. Mechanical properties of laser cut poly(L-lactide) micro-specimens: implications for stent design, manufacture, and sterilization. J Biomech Eng 2005;127:25-31. (Pubitemid 40463478)
91. Bunger CM, Grabow N, Sternberg K, Goosmann M, Schmitz KP, Kreutzer HJ et al. A biodegradable stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for peripheral vascular application: preliminary experience in the pig. J Endovasc Ther 2007; 14:725-33. (Pubitemid 47598200)
92. Bunger CM, Grabow N, Sternberg K, Kroger C, Ketner L, Schmitz KP et al. Sirolimus-eluting biodegradable poly-L-lactide stent for peripheral vascular application: a preliminary study in porcine carotid arteries. J Surg Res 2007;139:77-82. (Pubitemid 46482559)
93. 93- Grabow N, Bunger CM, Schultze C, Schmohl K, Martin DP, Williams SF et al. A biodegradable slotted tube stent based on poly(L-lactide) and poly(4-hydroxybutyrate) for rapid balloon-expansion. Ann Biomed Eng 2007;35:2031-2038 (Pubitemid 350165290)
94. Tammela TL, Talja M. Biodegradable urethral stents. BJU Int 2003;92:843-850
95. Palminteri E. Stents and urethral strictures: a lesson learned? European Urology 2008;54:498-500.
96. Uurto I, Kotsar A, Isotalo T, Mikkonen J, Martikainen PM, Kellomaki M et al. Tissue biocompatibility of new biodegradable drug-eluting stent materials. J Mater Sci Mater Med 2007;18:1543-1547 (Pubitemid 47030214)
97. Hietala EM, Salminen US, Stahls A, Valimaa T, Maasilta P, Tormala P et al. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res 2001;38: 361-369 (Pubitemid 32678951)
98. Mikkonen J, Uurto I, Isotalo T, Kotsar A, Tammela TLJ, Talja M et al. Drug-eluting bioabsorbable stents - An in vitro study. Acta Biomaterialia 2009;5:2894-2900
99. Nuutinen JP, Clerc C, Reinikainen R, Tormala P. Mechanical properties and in vitro degradation of bioabsorbable self-expanding braided stents. J Biomater Sci Polym Ed 2003;14:255-266 (Pubitemid 36442802)
100. Nuutinen JP, Clerc C, Tormala P. Theoretical and experimental evaluation of the radial force of self-expanding braided bioabsorbable stents. J Biomater Sci Polym Ed 2003;14:677-687